Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H.

J Virol. 2018 Nov 12;92(23). pii: e01143-18. doi: 10.1128/JVI.01143-18. Print 2018 Dec 1.

2.

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

Ratto-Kim S, Yoon IK, Paris RM, Excler JL, Kim JH, O'Connell RJ.

Front Immunol. 2018 Jun 21;9:1397. doi: 10.3389/fimmu.2018.01397. eCollection 2018. Review.

3.

Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders.

Ratto-Kim S, Schuetz A, Sithinamsuwan P, Barber J, Hutchings N, Lerdlum S, Fletcher JLK, Phuang-Ngern Y, Chuenarom W, Tipsuk S, Pothisri M, Jadwattanakul T, Jirajariyavej S, Sajjaweerawan C, Akapirat S, Chalermchai T, Suttichom D, Kaewboon B, Prueksakaew P, Karnsomlap P, Clifford D, Paul RH, de Souza MS, Kim JH, Ananworanich J, Valcour V.

AIDS Res Hum Retroviruses. 2018 Aug;34(8):685-689. doi: 10.1089/AID.2017.0237. Epub 2018 Jun 12.

PMID:
29737194
4.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

5.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Ngauy V, Sinangil F, Dawson P, deCamp AC, Phogat S, Garunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vandergrift N, Wills S, Tomaras GD, Robb ML, Michael NL, Kim JH, Vasan S, O'Connell RJ; RV305 Study Team.

J Infect Dis. 2017 Apr 15;215(8):1255-1263. doi: 10.1093/infdis/jix099.

6.

Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192a. No abstract available.

PMID:
27711066
7.

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

Liu F, Fan X, Auclair S, Ferguson M, Sun J, Soong L, Hou W, Redfield RR, Birx DL, Ratto-Kim S, Robb ML, Kim JH, Michael NL, Hu H.

PLoS Pathog. 2016 Jun 9;12(6):e1005663. doi: 10.1371/journal.ppat.1005663. eCollection 2016 Jun.

8.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G.

Nat Med. 2016 Jul;22(7):762-70. doi: 10.1038/nm.4105. Epub 2016 May 30. Erratum in: Nat Med. 2016 Oct 6;22(10 ):1192.

9.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH.

J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11.

10.

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

Hu H, Liu F, Kim J, Ratto-Kim S.

Expert Rev Vaccines. 2016 Jun;15(6):709-17. doi: 10.1586/14760584.2016.1147354. Epub 2016 Feb 17. Review.

11.

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1.

Allam A, Majji S, Peachman K, Jagodzinski L, Kim J, Ratto-Kim S, Wijayalath W, Merbah M, Kim JH, Michael NL, Alving CR, Casares S, Rao M.

Sci Rep. 2015 Jun 2;5:10443. doi: 10.1038/srep10443.

12.

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

Ratto-Kim S, de Souza MS, Currier JR, Karasavvas N, Sidney J, Rolland M, Valencia-Micolta A, Madnote S, Sette A, Nitayaphan S, Pitisuttuthum P, Kaewkungwal J, Rerks-Ngarm S, O'Connell R, Michael N, Robb ML, Marovich M, Kim JH.

PLoS One. 2015 Feb 9;10(2):e0115582. doi: 10.1371/journal.pone.0115582. eCollection 2015.

13.

Association between brain volumes and HAND in cART-naïve HIV+ individuals from Thailand.

Heaps JM, Sithinamsuwan P, Paul R, Lerdlum S, Pothisri M, Clifford D, Tipsuk S, Catella S, Busovaca E, Fletcher JL, Raudabaugh B, Ratto-Kim S, Valcour V, Ananworanich J; SEARCH 007/011 study groups.

J Neurovirol. 2015 Apr;21(2):105-12. doi: 10.1007/s13365-014-0309-8. Epub 2015 Jan 21.

14.

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

Dommaraju K, Kijak G, Carlson JM, Larsen BB, Tovanabutra S, Geraghty DE, Deng W, Maust BS, Edlefsen PT, Sanders-Buell E, Ratto-Kim S, deSouza MS, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Mullins JI, Kim JH, Rolland M.

PLoS One. 2014 Oct 28;9(10):e111334. doi: 10.1371/journal.pone.0111334. eCollection 2014.

15.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. doi: 10.1073/pnas.1400446111. Epub 2014 Sep 2.

16.

Designing the epitope flanking regions for optimal generation of CTL epitopes.

Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

Vaccine. 2014 Jun 12;32(28):3509-16. doi: 10.1016/j.vaccine.2014.04.039. Epub 2014 May 2.

PMID:
24795226
17.

Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND.

Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, Tipsuk S, Fletcher JL, Degruttola V, Ratto-Kim S, Hutchings N, Shikuma C, Ananworanich J; SEARCH 007 and 011 study groups.

J Neurovirol. 2013 Apr;19(2):137-43. doi: 10.1007/s13365-013-0151-4. Epub 2013 Mar 13.

18.

Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.

Hu H, Nau M, Ehrenberg P, Chenine AL, Macedo C, Zhou Y, Daye ZJ, Wei Z, Vahey M, Michael NL, Kim JH, Marovich M, Ratto-Kim S.

Blood. 2013 Feb 14;121(7):1136-44. doi: 10.1182/blood-2012-07-446278. Epub 2012 Dec 20.

19.

Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection.

Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, Pothisri M, Busovaca E, Ratto-Kim S, Jagodzinski L, Spudich S, Michael N, Kim JH, Valcour V; RV254/SEARCH 010 protocol teams.

PLoS One. 2012;7(11):e49272. doi: 10.1371/journal.pone.0049272. Epub 2012 Nov 16.

20.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

21.

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.

Steers NJ, Ratto-Kim S, de Souza MS, Currier JR, Kim JH, Michael NL, Alving CR, Rao M.

PLoS One. 2012;7(8):e42579. doi: 10.1371/journal.pone.0042579. Epub 2012 Aug 6.

22.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.

Eller MA, Eller LA, Ratto-Kim S, Ouma BJ, Lo V, de Souza M, Guwatudde D, Nails B, Michael NL, Wabwire-Mangen F, Robb ML, Marovich MA, Sandberg JK, Currier JR.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):9-18. doi: 10.1097/QAI.0b013e31825c1217.

PMID:
22580564
23.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.

24.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

25.

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.

Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA; Thai AIDS Vaccine Evaluation Group.

Vaccine. 2012 Jan 20;30(5):832-6. doi: 10.1016/j.vaccine.2011.11.002. Epub 2011 Nov 12.

PMID:
22085554
26.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

27.

HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study.

Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, Siangphoe U, Kim JH, de Souza M, Degruttola V, Paul RH, Shikuma CM; Southeast Asia Research Collaboration with the University of Hawaii 001 protocol team.

Neurology. 2009 Mar 17;72(11):992-8. doi: 10.1212/01.wnl.0000344404.12759.83.

28.

Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand.

Ratto-Kim S, Chuenchitra T, Pulliam L, Paris R, Sukwit S, Gongwon S, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Shiramizu BT, de Souza MS, Chitpatima ST, Sun B, Rempel H, Nitayaphan S, Williams K, Kim JH, Shikuma CM, Valcour VG; Southeast Asia Research Collaboration with the University of Hawaii (SEARCH) 001 protocol team.

J Neuroimmunol. 2008 Mar;195(1-2):100-7. doi: 10.1016/j.jneuroim.2007.11.021. Epub 2008 Jan 11.

29.

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Currier JR, Galley LM, Wenschuh H, Morafo V, Ratto-Kim S, Gray CM, Maboko L, Hoelscher M, Marovich MA, Cox JH.

Clin Vaccine Immunol. 2008 Feb;15(2):267-76. Epub 2007 Dec 12.

30.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.

PMID:
17909315
31.

Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV-1 infection.

Valcour VG, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Ratto-Kim S, Apateerapong W, Shiramizu BT, Desouza MS, Chitpatima ST, Watt G, Chuenchitra T, Robertson KR, Paul RH, McArthur JC, Kim JH, Shikuma CM.

Neurology. 2007 Feb 13;68(7):525-7.

PMID:
17296919
32.

HIV DNA and dementia in treatment-naïve HIV-1-infected individuals in Bangkok, Thailand.

Shiramizu B, Ratto-Kim S, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Watt G, deSouza M, Chuenchitra T, Sukwit S, Chitpatima S, Robertson K, Paul R, Shikuma C, Valcour V.

Int J Med Sci. 2006 Dec 6;4(1):13-8.

33.

Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia.

Killebrew DA, Troelstrup D, Valcour V, Williams A, Aguon J, Sapalo D, Shikuma C, Ratto-Kim S, Shiramizu B.

Cell Mol Biol (Noisy-le-grand). 2005 Sep 2;51 Suppl:OL745-54.

PMID:
16171574
34.

HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages?

Shikuma CM, Valcour VG, Ratto-Kim S, Williams AE, Souza S, Gerschenson M, Day L, Kim JH, Shiramizu B.

Clin Infect Dis. 2005 Jun 15;40(12):1846-8. Epub 2005 May 3.

PMID:
15909275
35.

Circulating proviral HIV DNA and HIV-associated dementia.

Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, Aguon J, Valcour V.

AIDS. 2005 Jan 3;19(1):45-52.

36.

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J, Thapinta D, Garner R, Bussaratid V, Singharaj P, el-Habib R, Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE; Thai AIDS Vaccine Evaluation Group.

J Infect Dis. 2004 Aug 15;190(4):702-6. Epub 2004 Jul 20.

PMID:
15272397
37.

Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons.

Bernstein WB, Cox JH, Aronson NE, Tracy L, Schlienger K, Ratto-Kim S, Garner R, Cotte J, Zheng Z, Winestone L, Liebig C, Galley LM, Connors M, Birx DL, Carroll RG, Levine BL.

Clin Immunol. 2004 Jun;111(3):262-74.

PMID:
15183147
38.

Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.

Ratto-Kim S, Garner RP, Kim JH, Jagodzinski LL, Michael NL, Paris R, Redfield RR, Birx DL.

J Infect Dis. 2004 Jun 1;189(11):1988-95. Epub 2004 Apr 30.

PMID:
15143464
39.

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, Chuenchitra T, Garner RP, Thapinta D, Polonis V, Ratto-Kim S, Chanbancherd P, Chiu J, Birx DL, Duliege AM, McNeil JG, Brown AE; Thai AIDS Vaccine Evaluation Group.

J Infect Dis. 2003 Jul 15;188(2):219-27. Epub 2003 Jul 3.

PMID:
12854076
40.

Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.

Ratto-Kim S, Loomis-Price LD, Aronson N, Grimes J, Hill C, Williams C, El Habib R, Birx DL, Kim JH.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):9-17.

PMID:
12514409
41.

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.

Marovich MA, Mascola JR, Eller MA, Louder MK, Caudrelier PA, El-Habib R, Ratto-Kim S, Cox JH, Currier JR, Levine BL, June CH, Bernstein WB, Robb ML, Schuler-Thurner B, Steinman RM, Birx DL, Schlesinger-Frankel S.

J Infect Dis. 2002 Nov 1;186(9):1242-52. Epub 2002 Oct 7.

PMID:
12402193
42.

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, Humphries MJ, Ratto-Kim S, Birx DL, Steffens C, Landay A, Carroll RG, June CH.

Nat Med. 2002 Jan;8(1):47-53.

PMID:
11786906
43.

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120.

Hioe CE, Tuen M, Chien PC Jr, Jones G, Ratto-Kim S, Norris PJ, Moretto WJ, Nixon DF, Gorny MK, Zolla-Pazner S.

J Virol. 2001 Nov;75(22):10950-7.

44.

Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.

Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, Michael NL, Jagodzinski L, Hawkes C, Mayers D, Gilliam BL, Birx DC, Robb ML.

AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1021-34.

PMID:
11485619
45.

Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.

Hioe CE, Jones GJ, Rees AD, Ratto-Kim S, Birx D, Münz C, Gorny MK, Tuen M, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):893-905.

PMID:
10875615
46.

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, Redfield RR.

J Infect Dis. 2000 Mar;181(3):881-9.

PMID:
10720508
47.

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.

Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, Duliege AM, Chuenchitra C, Supapongse T, Rungruengthanakit K, deSouza M, Mascola JR, Boggio K, Ratto-Kim S, Markowitz LE, Birx D, Suriyanon V, McNeil JG, Brown AE, Michael RA.

Vaccine. 2000 Feb 14;18(15):1448-55.

PMID:
10618542
48.

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.

Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jarosinski P, Walsek CM, Brouwers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, Wood LV.

J Infect Dis. 1999 Sep;180(3):626-40.

PMID:
10438349
49.

Varicella immunity: persistent serologic non-response to immunization.

Katial RK, Ratto-Kim S, Sitz KV, Moriarity R, Engler RJ.

Ann Allergy Asthma Immunol. 1999 May;82(5):431-4.

PMID:
10353572

Supplemental Content

Loading ...
Support Center